Mycobacterium hsp65 DNA entrapped into TDM-loaded PLGA microspheres induces protection in mice against Leishmania (Leishmania) major infection
- 119 Downloads
Heat shock proteins (HSPs) are highly conserved among different organisms. A mycobacterial HSP65 DNA vaccine was previously shown to have prophylactic and immunotherapeutic effects against Mycobacterium tuberculosis infection in mice. Here, BALB/c mice were immunized with mycobacterial DNA-hsp65 or with DNA-hsp65 and trehalose dymicolate (TDM), both carried by biodegradable microspheres (MHSP/TDM), and challenged with Leishmania (Leishmania) major. MHSP/TDM conferred protection against L. major infection, as indicated by a significant reduction of edema and parasite loads in infected tissues. Although high levels of interferon-γ and low levels of interleukin (IL)-4 and IL-10 were detected in mice immunized with DNA-hsp65 or MHSP/TDM, only animals immunized with MHSP/TDM displayed a consistent Th1 immune response, i.e., significantly higher levels of anti-soluble Leishmania antigen (SLA) immunoglobulin G (IgG)2a and low anti-SLA IgG1 antibodies. These findings indicate that encapsulated MHSP/TDM is more immunogenic than naked hsp65 DNA, and has great potential to improve vaccine effectiveness against leishmaniasis and tuberculosis.
KeywordsLeishmaniasis PLGA Microsphere Major Infection Challenge Infection IgG2a Antibody
This work received financial support from FAPEMIG, FAPESP, CNPq, and Institutes of Millennium REDE-TB (MCT).
- Alimoharrunadian MH, Khamesipour A, Darabi H, Firooz A, Malekzadeh S, Bahonar A, Dowlati Y, Moddaber F (2002) The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis. Vaccine 21:174–180CrossRefPubMedGoogle Scholar
- Barrios C, Lussow AR, Van Embden J, Van Der Zee R, Rappuoli R, Costantino P, Louis JA, Lambert PH, Del Giudice G (1992) Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guérin priming. Eur J Immunol 22:1365–1372PubMedGoogle Scholar
- Coelho EA, Tavares CA, Carvalho FA, Chaves KF, Teixeira KN, Rodrigues RC, Charest H, Matlashewski G, Gazzinelli RT, Fernandes AP (2003) Immune response induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun 71:3988–3994PubMedGoogle Scholar
- Fernandes AP, Herrera EC, Mayrink W, Gazzinelli RT, Liu WY, Costa CA, Tavares CAP, Melo MN, Michalick MSM, Gentz R, Nascimento E (1997) Immune responses induced by a Leishmania (Leishmania) amazonensis recombinant antigen in mice and lymphocytes from vaccinated subjects. Rev Inst Med Trop São Paulo 39:70–78Google Scholar
- Launois P, Maillard I, Pingel S, Swihart KG, Xénarios I, Acha-Orbea H, Diggelmann H, Locksley RM, Mac-Donald HR, Louis JA (1997) IL-4 rapidly produced by Vβ4+ Vα8+ CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 6:541–549CrossRefPubMedGoogle Scholar
- Lima KM, Dos Santos AS, Lima VM, Coelho-Castelo AA, Rodrigues JM Jr, Silva CL (2003a) Single dose of a vaccine based on DNA encoding mycobacterial hsp65 protein plus TDM-loaded PLGA microspheres protects mice against a virulent strain of Mycobacterium tuberculosis. Gene Ther 10:678–685CrossRefPubMedGoogle Scholar
- World Health Organization (2005) Program for surveillance and control of leishmaniaisis. http://who.int/emc/diseases/leish/index.html.2005 (generic)